This review highlights the pathophysiology and potential cardiovascular risks of hypertriglyceridemia in pediatric patients with diabetes mellitus, emphasizing the need for more data to guide clinical practice.
Answers are grounded in this paper and cite their sources.
Highlights need for early lipid screening in pediatric DM; leaves open optimal management and long-term CVD impact.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). It is estimated that the risk of CVD in diabetes mellitus (DM) is 2 to 10 times higher than in the general population. Much of this increased risk is thought to be related to the development of an atherogenic lipid profile, in which hypertriglyceridemia is an essential component. Recent studies suggest that dyslipidemia may be present in children and adolescents with DM, particularly in T2DM and in association with poor control in T1DM. However, the role of hypertriglyceridemia in the development of future CVD in youth with DM is unclear, as data are scarce. In this review, we will evaluate the pathophysiology of atherogenic hypertriglyceridemia in DM, the evidence regarding an independent role of triglycerides in the development of CVD, and the treatment of hypertriglyceridemia in patients with DM, highlighting the potential relevance to children and the need for more data in children and adolescents to guide clinical practice.
No takes yet. Share an insight, caveat, or question.
Hartz et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: